先声药业

两家较老牌药企，江苏豪森医药（Hansoh）和先声药业（Simcere），据报道也计划今年晚些时候赴香港IPO。

Meanwhile , two more established drugmakers , Jiangsu Hansoh and Simcere , are reportedly plotting Hong Kong IPOs later this year .

一些中国制药商正在尝试完成从仿制药到创新药的飞跃，先声药业（SimcerePharmaceuticals）就是其中一家，它最近在南京成立了研发中心。

One of those trying to make the leap from generic to innovative medicines is Simcere Pharmaceuticals , which recently opened an R & D hub in Nanjing .

还有先声药业和江苏林洋新能源有限公司与弘毅投资的合作等等。

Just as Simcere Pharmaceuticals and Solarfun Power had done with Hony Capital .

先声药业创始人兼董事会主席任晋生表示，资金仍然是个难题。

Ren Jinsheng , the company 's founder and chairman , says funding remains a challenge .

恩度是利用先声药业开发团队的原创研究开发的，但并不包含中药所用的草药。任晋生说，去年这种药物的销售额在3380万美元左右。

Endo , which was developed with original research by Simcere 's development team but doesn 't contain herbs used in traditional Chinese medicine , had about $ 33.8 million in sales last year , said Mr.